Genelux (NASDAQ:GNLX) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Posted by Adam Dyson on Mar 28th, 2025

Genelux (NASDAQ:GNLX – Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09), Zacks reports.

Genelux Stock Up 1.7 %

NASDAQ GNLX opened at $3.08 on Friday. The firm has a 50-day moving average price of $4.06 and a two-hundred day moving average price of $3.10. Genelux has a 12-month low of $1.60 and a 12-month high of $6.50. The company has a market capitalization of $106.38 million, a P/E ratio of -3.24 and a beta of -1.41.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Genelux in a research report on Tuesday. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $18.25.

Check Out Our Latest Stock Analysis on Genelux

Genelux Company Profile

(Get Free Report)

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.